Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks...

|About: Valeant Pharmaceuticals Int... (VRX)|By:, SA News Editor

Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks to buy Actavis (ACT) for $13B in a deal billed as a "merger of equals" that would pay ACT shareholders a slight premium. Earlier this month, the two companies settled patent litigation surrounding NDA applications for generic versions of Zyclara and Ziana. Asked for comment, a Valeant spokesperson tells WSJ only: "We're a very acquisitive company."